 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| 12345678910111213...235236» |
- methotrexate / Generic mfg.
Trapped in the System: Methotrexate Toxicity in a Patient on Peritoneal Dialysis () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_811;
Clinicians should exercise caution and consider alternative therapies. If its use is crucial such as in our case, we recommend prioritizing close monitoring to detect early signs of toxicity.
- methotrexate / Generic mfg.
Methotrexate and Kidney Function: Differential Effects of High versus Low-Dose () - Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_693;
The patient was continued on isotonic bicarbonate, leucovorin, and received glucarpidase...In contrast, LD-MTX has not definitively been associated with kidney dysfunction. In patients taking LD-MTX, considerations of alternative etiologies for declines in eGFR should be explored.Conclusion When evaluating acute kidney injury in patients who are taking methotrexate, medication dose and associated risk for nephrotoxicity must be considered.
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Tumor mutational burden: NIVACOR: Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (clinicaltrials.gov) - Mar 13, 2025
P2, N=73, Completed, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
In patients taking LD-MTX, considerations of alternative etiologies for declines in eGFR should be explored.Conclusion When evaluating acute kidney injury in patients who are taking methotrexate, medication dose and associated risk for nephrotoxicity must be considered. Unknown status --> Completed | Trial completion date: Sep 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Aug 2024
- || Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Tukysa (tucatinib) / Pfizer, Perjeta (pertuzumab) / Roche
Review, Journal: HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers. (Pubmed Central) - Mar 12, 2025
This review aims to summarize the rapidly evolving landscape of HER2-directed agents for BTCs, highlighting current evidence of survival benefit. Beginning with a concise presentation of the structural and functional aspects of HER2, we detail the frequency and prognostic significance of HER2 alterations in BTCs and discuss all available preclinical and clinical data on anti-HER2 agents tested for BTCs.
- || MK-1084 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Mar 12, 2025
P1, N=830, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Beginning with a concise presentation of the structural and functional aspects of HER2, we detail the frequency and prognostic significance of HER2 alterations in BTCs and discuss all available preclinical and clinical data on anti-HER2 agents tested for BTCs. Trial completion date: Aug 2027 --> Feb 2030 | Trial primary completion date: Aug 2027 --> Feb 2030
- | BNT327 / BioNTech
Enrollment closed: PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 12, 2025
P2, N=35, Active, not recruiting, Sponsor: Biotheus Inc.
Trial completion date: Aug 2027 --> Feb 2030 | Trial primary completion date: Aug 2027 --> Feb 2030 Recruiting --> Active, not recruiting
- | Journal: Olfactory Effects of Chemotherapy Combined with Bevacizumab on Advanced-Stage Colorectal Cancer Patients: Chemotherapy and Olfaction. (Pubmed Central) - Mar 12, 2025
Statistically significant decrease was observed in post-treatment D and TDI scores (p?=?0.015 and p?=?0.035, respectively). FOLFOXIRI combined with Bevacizumab, may affect olfactory functions Informing patients about this aspect before treatment could be beneficial.
- || Clinical, Journal: Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial. (Pubmed Central) - Mar 11, 2025
Nano-silymarin may be considered an adjuvant medication for the prevention of certain chemotherapy-induced adverse reactions. Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation.
- ||||| Ampligen (rintatolimod) / AIM ImmunoTech
Trial suspension: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) - Mar 10, 2025
P2, N=90, Suspended, Sponsor: AIM ImmunoTech Inc.
Further research with larger sample sizes and various doses of nano-silymarin is recommended for a more comprehensive evaluation. Recruiting --> Suspended
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Review, Journal: Adjuvant Chemotherapy in Colon Cancer: Simple is Better (Pubmed Central) - Mar 10, 2025
Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients-especially due to their limited mobility, comorbidities, and polypharmacy.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis. (Pubmed Central) - Mar 9, 2025
There also needs to be special consideration for the geriatric patients-especially due to their limited mobility, comorbidities, and polypharmacy. In comparison with PA-HAIC alone, PA-HAIC combined with PD-1 inhibitors could improve the DFS benefits with acceptable safety profiles in HCC patients with MVI.
- | Retrospective data, Journal: The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma. (Pubmed Central) - Mar 9, 2025
First-line FOLFOX treatment is suitable for patients with advanced ESCC. However, FOLFOX has shown limited efficacy as a later-line treatment.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Gut microbiota derived DCA enhances FOLFOX efficacy via Ugt1a6b mediated enterohepatic circulation in colon cancer. (Pubmed Central) - Mar 9, 2025
FOLFOX (5-Fluorouracil, Calcium Folinate combined with Oxaliplatin) is a preferred chemotherapy regimen for colon cancer, but its limited efficacy remains a major challenge, significantly impairs patient outcomes...We first demonstrated that bile acids depletion (cholestyramine treatment) enhanced FOLFOX efficacy in an orthotopic colon cancer mouse model, suggesting that bile acids play a key role in FOLFOX's therapeutic effects...Transcriptomic analysis and subsequent biological experiments revealed that DCA enhanced FOLFOX efficacy via Ugt1a6b. In conclusion, our findings establish that gut microbiota-derived DCA enhances the efficacy of FOLFOX potentially via Ugt1a6b mediated enterohepatic circulation, providing novel insights into a synergistic therapeutic strategy for improving colon cancer treatment.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF-?B Pathway. (Pubmed Central) - Mar 7, 2025
In conclusion, our findings establish that gut microbiota-derived DCA enhances the efficacy of FOLFOX potentially via Ugt1a6b mediated enterohepatic circulation, providing novel insights into a synergistic therapeutic strategy for improving colon cancer treatment. Thus, our findings demonstrate that MALT1 suppression dramatically reduces FOLFOX-induced inflammatory and fibrotic conditions by modulating the NF-?B activation, paving the way for innovative HSOS therapy approaches.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Metastases: Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study. (Pubmed Central) - Mar 7, 2025
Thus, our findings demonstrate that MALT1 suppression dramatically reduces FOLFOX-induced inflammatory and fibrotic conditions by modulating the NF-?B activation, paving the way for innovative HSOS therapy approaches. Compared with SC, triple combination therapy comprising HAIC, targeted therapy and immunotherapy appears to be an effective and safe treatment for advanced iCCA.
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Imaging-based surrogate classification for risk stratification of hepatocellular carcinoma with microvascular invasion to adjuvant hepatic arterial infusion chemotherapy: a multicenter retrospective study. (Pubmed Central) - Mar 7, 2025
P3
Compared with SC, triple combination therapy comprising HAIC, targeted therapy and immunotherapy appears to be an effective and safe treatment for advanced iCCA. The utilization of this imaging-based model could help to better characterize MVI-positive HCC patients and facilitate the precise subtyping of patients who genuinely benefit from adjuvant HAIC treatment.
- || 5-fluorouracil / Generic mfg.
Clinical, Journal, Metastases: Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high-risk: A propensity score matching study. (Pubmed Central) - Mar 7, 2025
FOLFOX-based hepatic arterial infusion chemotherapy plus TKI and PD-1 inhibitors significantly improve survival prognosis compared with TKI plus PD-1 inhibitors. This is a potential first-line treatment for high-risk aHCC, with a relatively controlled safety profile.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort. (Pubmed Central) - Mar 6, 2025
This is a potential first-line treatment for high-risk aHCC, with a relatively controlled safety profile. Adjuvant modified FOLFIRINOX was effective and tolerated in patients with resected PDAC in a nontrial setting, including for patients older than 70?years of age.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Cryoablation Combined with Lenvatinib Plus Tislelizumab Compared with FOLFOX in Patients with Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) (clinicaltrials.gov) - Mar 6, 2025
P2, N=92, Not yet recruiting, Sponsor: Fudan University
- | Lumakras (sotorasib) / Amgen
Trial completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Mar 6, 2025
P1, N=1200, Recruiting, Sponsor: Amgen
Adjuvant modified FOLFIRINOX was effective and tolerated in patients with resected PDAC in a nontrial setting, including for patients older than 70?years of age. Trial completion date: Mar 2028 --> Dec 2027
- | Trial primary completion date: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer (clinicaltrials.gov) - Mar 6, 2025
P3, N=1020, Recruiting, Sponsor: Karolinska University Hospital
Trial completion date: Mar 2028 --> Dec 2027 Trial primary completion date: Sep 2026 --> Dec 2026
- | Journal: Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. (Pubmed Central) - Mar 6, 2025
Trial primary completion date: Sep 2026 --> Dec 2026 Addition of oxaliplatin or nab-paclitaxel to nal-IRI/FL was significantly associated with a better OS than regimen shifting after progression on nal-IRI/FL in patients with metastatic PDAC.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: GASTFOX: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA (clinicaltrials.gov) - Mar 5, 2025
P3, N=507, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Addition of oxaliplatin or nab-paclitaxel to nal-IRI/FL was significantly associated with a better OS than regimen shifting after progression on nal-IRI/FL in patients with metastatic PDAC. Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Onivyde (nanoliposomal irinotecan) / Ipsen
Journal, Real-world evidence, Real-world, Metastases: Efficacy of liposomal irinotecan?+?5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. (Pubmed Central) - Mar 4, 2025
Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025 These findings support the use of nal-IRI?+?5-FU/LV as standard second-line treatment for PC patients after gemcitabine-based chemotherapy.
- | Zirabev (bevacizumab-bvzr) / Pfizer, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
Reimbursement, US reimbursement, Journal, Medicare: Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare. (Pubmed Central) - Mar 4, 2025
The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of bevacizumab-bvzr in mCRC and mNSCLC in Medicare.Methods We developed a Medicare payer perspective simulation model of patients treated for mCRC and mNSCLC to estimate cost-savings from converting bevacizumab (originator) to bevacizumab-bvzr or alternative biosimilars such as bevacizumab-awwb, -maly, and -abcd...At 100% conversion, monthly savings from biosimilar conversion could fund up to 13,887 additional mCRC patient-months of treatment with bevacizumab-bvzr?+?FOLFOX, and up to 8,959 additional mNSCLC patient-months of treatment with bevacizumab-bvzr?+?paclitaxel?+?carboplatin...The biosimilar NNC from other biosimilars ranged from 60-4,564 and 55-4,422 for mCRC and NSCLC, respectively.Conclusion In the first cost-efficiency and expanded access study of biosimilar bevacizumab in mCRC and mNSCLC, we find that bevacizumab-bvzr-based regimens can result in substantial cost savings relative to originator-based first line treatment in Medicare. These cost savings could be reinvested to treat a substantial number of additional patients with mCRC or mNSCLC, or fund other costs of care in Medicare, on a budget-neutral basis.
- | Rybrevant (amivantamab-vmjw) / J&J
New P2 trial: An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment. (clinicaltrials.gov) - Mar 4, 2025
P2, N=85, Not yet recruiting, Sponsor: Yonsei University
- | Journal: Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. (Pubmed Central) - Mar 3, 2025
Plasma miR-379 appears clinically useful as a predictive biomarker to identify which patients with advanced PDAC benefit most from treatment with FOLFIRINOX or gemcitabine-nab-paclitaxel. Further validation in larger studies and clinical trials is now warranted.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Journal: Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. (Pubmed Central) - Mar 3, 2025
An NLR ratio less than 4 was significantly associated with longer OS (p?=?0.001). Low MBM is linked to FOLFIRINOX toxicity, suggesting MBM assessment could allow better selection of patients to avoid these toxicities, warranting further confirmation in larger cohorts.
- || Avastin (bevacizumab) / Roche
P2 data, Journal: FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial. (Pubmed Central) - Mar 3, 2025
P1/2
Low MBM is linked to FOLFIRINOX toxicity, suggesting MBM assessment could allow better selection of patients to avoid these toxicities, warranting further confirmation in larger cohorts. The regimen tested consisted of bevacizumab (5?mg/kg), folinic acid(400?mg/m
- | Sulanda (surufatinib) / Hutchmed, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Journal, Metastases: Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma. (Pubmed Central) - Mar 3, 2025
The regimen tested consisted of bevacizumab (5?mg/kg), folinic acid(400?mg/m This study provides promising clinical guidance for the treatment of advanced cholangiocarcinoma and is expected to modify the treatment strategy for this disease.
- | 5-fluorouracil / Generic mfg.
Journal: Microglia-Mediated Synaptic Dysfunction Contributes to Chemotherapy-Related Cognitive Impairment. (Pubmed Central) - Feb 28, 2025
Cotreatment with the microglial inhibitor minocycline (33?mg/kg, daily for 3?weeks) restored cognitive deficits and microglial ramification, decreased the number of CD68-positive microglia, and reversed the reductions in LTP and the amplitude of NMDAR-EPSCs in 5-Fu/LV-treated mice. Our data suggest that microglial dysfunction and related synaptic dysfunction contribute to 5-Fu/LV-induced cognitive impairment.
- || Natrunix (vilamakitug) / XBiotech
Enrollment closed, Trial completion date: 1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 28, 2025
P1/2, N=76, Active, not recruiting, Sponsor: XBiotech, Inc.
Our data suggest that microglial dysfunction and related synaptic dysfunction contribute to 5-Fu/LV-induced cognitive impairment. Completed --> Active, not recruiting | Trial completion date: Jun 2024 --> Jun 2025
- | Journal: Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges. (Pubmed Central) - Feb 28, 2025
Nevertheless, some questions remain: the application in elderly patients, the addition of immunotherapy in patients with microsatellite instability or with high PD-L1 levels, comparison with chemoradiotherapy in junctional cancers and real cure rates. The FLOT regimen has revolutionized the treatment of resectable gastric cancer, but caution is needed before considering it an absolute standard of care.
- | irinotecan / Generic mfg.
Journal: Irinotecan-induced dysarthria and management. (Pubmed Central) - Feb 28, 2025
The FLOT regimen has revolutionized the treatment of resectable gastric cancer, but caution is needed before considering it an absolute standard of care. Prolonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan.
- |||| SHR-1826 / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 27, 2025
P1/2, N=876, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Prolonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan. Not yet recruiting --> Recruiting
- ||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, ligufalimab (AK117) / Akesobio
Enrollment change, Trial completion date, Trial primary completion date: AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 27, 2025
P2, N=254, Recruiting, Sponsor: Akeso
Not yet recruiting --> Recruiting N=104 --> 254 | Trial completion date: Dec 2026 --> Aug 2028 | Trial primary completion date: Dec 2024 --> May 2026
- || New P2 trial: ENACT: Acoustic Cluster Therapy (ACT) with Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Feb 27, 2025
P2, N=25, Not yet recruiting, Sponsor: EXACT Therapeutics AS
- || Retrospective data, Review, Journal: Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis. (Pubmed Central) - Feb 27, 2025
This literature-based meta-analysis was performed with keywords related to VEGF gene polymorphisms and clinical response in esophageal squamous carcinoma patients receiving pharmaceutical therapy (including 5-FU, cisplatin, oxaliplatin, and calcium folinate)...The presence of VEGF G-1154A and VEGF-634C/G was found to be correlated with patient response to 5-FU/CDDP-based treatment, whereas VEGF-2549I/D was correlated with response to 5-FU/oxaliplatin-based treatment, and VEGF-936C/T was associated with both 5-FU/CDDP- and 5-FU/oxaliplatin-based treatment response. VEGF gene polymorphisms affect the response of esophageal squamous carcinoma patients receiving pharmaceutical therapy, especially 5-FU-based treatments.
- || Review, Journal: Pancreatic Mixed Acinar-neuroendocrine Carcinoma in a Patient With a Germline PTEN Variant: A Case Report and Genomic Literature Review. (Pubmed Central) - Feb 27, 2025
The absence of KRAS mutation and presence of germline PTEN variant may have contributed to the aggressive clinical course and treatment resistance. These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies.
- | Trial completion date, Trial primary completion date: Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 26, 2025
P1, N=20, Recruiting, Sponsor: University of Louisville
These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies. Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Jul 2026
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New trial, HEOR: NEOCIPN-COLON: Neoadjuvant FOLFOX Chemotherapy for Colon Cancer: Long-Term Chemotherapy-Induced Peripheral Neuropathy and Impact on Quality of Life (clinicaltrials.gov) - Feb 26, 2025
P=N/A, N=54, Completed, Sponsor: P. Herzen Moscow Oncology Research Institute
- | Trial completion: SHORT-FOX: Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer (clinicaltrials.gov) - Feb 26, 2025
P2, N=38, Completed, Sponsor: Stanford University
Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Jul 2026 Active, not recruiting --> Completed
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion, Trial completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Feb 26, 2025
P2, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> Dec 2024
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Mismatch repair: CheckMate 8HW: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 26, 2025
P3, N=1147, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> Dec 2024 Recruiting --> Active, not recruiting
- || P2 data, Journal, Metastases: Efficacy and Safety of KH903 Plus FOLFIRI as a Second-Line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study. (Pubmed Central) - Feb 24, 2025
Recruiting --> Active, not recruiting KH903 in combination with FORFIRI in second-line treatment of patients with mCRC showed prolonged mPFS and mOS, comparing to the similar agents (Avastin
- | Journal, Metastases: Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study). (Pubmed Central) - Feb 24, 2025
KH903 in combination with FORFIRI in second-line treatment of patients with mCRC showed prolonged mPFS and mOS, comparing to the similar agents (Avastin Although the retrospective fashion, CTr/r proved to be a valuable option in this setting in a real-world context, providing superior outcomes compared to standard of care agents at the price of a moderate toxicity.
- | leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
Journal: Topological Descriptors of Colorectal Cancer Drugs and Characterizing Physical Properties Via QSPR Analysis. (Pubmed Central) - Feb 24, 2025
Current work on TIs and QSPR modeling shows a good correlation with physical properties. Moreover, estimated drug results depict and predict the physical properties in an efficient way.
- | methotrexate / Generic mfg.
Journal: Dendritic Molecular Baskets for Selective Binding of Toxic Methotrexate. (Pubmed Central) - Feb 24, 2025
While the host is biocompatible (HEK293; IC50 > 150 ?M) and produces inclusion complex [MTX?6]14- in cell media, it experiences limitation in pharmacokinetic sequestration of MTX2- as dihydrofolate reductase's affinity to the drug is suggested to prevail over that of 612-. Nonetheless, considering the basket's biocompatibility, tunability, and chemoselectivity, it stands as the leading candidate in the pursuit of an effective abiotic antidote for methotrexate poisoning.
- | 5-fluorouracil / Generic mfg.
Journal: Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients. (Pubmed Central) - Feb 24, 2025
PPI usage did not significantly influence mPR or OS following neoadjuvant fluoropyrimidine-based chemotherapy in resected PDAC patients. Further analysis of all patients, not just those who underwent resection, is required.
- || GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
P1 data, Journal, Tumor cell: Phase I Study of Adjuvant Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine, Low Dose Cyclophosphamide, and SBRT followed by FFX in High-Risk Resected Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Feb 23, 2025
This is the first prospective trial to evaluate adjuvant GVAX, Cy, SBRT, and mFFX in resected PDAC patients with high-risk features. This combination regimen was well tolerated with limited toxicity and promising survival outcomes, warranting future studies to validate this regimen in the adjuvant setting.